There was no significant difference in overall survival between groups ( median overall survival @ months -LSB- @ % CI @-@ -RSB- in the doxorubicin group vs @ months -LSB- @-@ -RSB- in the doxorubicin and ifosfamide group ; hazard ratio -LSB- HR -RSB- @ -LSB- @ % CI @-@ -RSB- ; stratified log-rank test p = @ ) .